Regen BioPharma (RGBP) EBIAT (2016 - 2025)
Historic EBIAT for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to -$572469.0.
- Regen BioPharma's EBIAT fell 11143.98% to -$572469.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 4597.7%. This contributed to the annual value of -$1.3 million for FY2025, which is 9072.09% down from last year.
- As of Q3 2025, Regen BioPharma's EBIAT stood at -$572469.0, which was down 11143.98% from -$167292.0 recorded in Q2 2025.
- Regen BioPharma's 5-year EBIAT high stood at $67.0 million for Q2 2022, and its period low was -$67.1 million during Q1 2022.
- Over the past 5 years, Regen BioPharma's median EBIAT value was -$130120.0 (recorded in 2024), while the average stood at -$367323.2.
- The largest annual percentage gain for Regen BioPharma's EBIAT in the last 5 years was 99407.33% (2022), contrasted with its biggest fall of 1527054.91% (2022).
- Over the past 5 years, Regen BioPharma's EBIAT (Quarter) stood at $2.6 million in 2021, then tumbled by 38.16% to $1.6 million in 2022, then plummeted by 121.38% to -$349760.0 in 2023, then tumbled by 47.35% to -$515384.0 in 2024, then decreased by 11.08% to -$572469.0 in 2025.
- Its EBIAT stands at -$572469.0 for Q3 2025, versus -$167292.0 for Q2 2025 and -$19354.0 for Q1 2025.